Form 6-K Ascendis Pharma A/S For: Sep 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI
September 17, 2024 6:32 AM EDTEvercore ISI analyst Josh Schimmer raised the price target on Ascendis Pharma (NASDAQ: ASND) to $205.00 (from $191.00) while maintaining a Outperform rating.
The analyst comments "Were still refining some estimates via HCP calls. For now, we model $450M peak TransCON CNP sales in achon. For... More
Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
September 16, 2024 4:35 PM EDTJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.
The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
September 16, 2024 12:07 PM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $175.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "ASND could be on its way to a third approved product using its long-acting TransCon technology. Today, it announced positive topline results for... More
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
September 16, 2024 12:06 PM EDTGoldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $180.00) while maintaining a Buy rating.
The analyst comments "Topline ApproaCH data indicate clear clinical benefit for TransCon CNP and competitive efficacy/safety/convenience profile; looking to detailed data and... More
Stifel on Ascendis Pharma (ASND): 'A Clear Win Following Recent Commercial Setbacks'
September 16, 2024 10:25 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "TransCon CNP succeeded in the Ph2/3 ApproaCH study in achondroplasia. On the primary endpoint of annualized growth velocity (AGV) the drug achieved a 1.49cm/yr delta vs. placebo (p... More
